{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:36:58Z","timestamp":1774679818651,"version":"3.50.1"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.lungcan.2016.05.023","type":"journal-article","created":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T22:53:22Z","timestamp":1464908002000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy"],"prefix":"10.1016","volume":"107","clinical-trial-number":[{"clinical-trial-number":"nct01829971","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Marco","family":"Tomasetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Amati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lory","family":"Santarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.05.023_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","article-title":"Lung cancer statistics","volume":"893","author":"Torre","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0020","first-page":"319","article-title":"Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health","volume":"110","author":"Neumann","year":"2013","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0025","first-page":"205","article-title":"Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutation","volume":"3","author":"Mitsudomi","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0030","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-15-2388","article-title":"IL-6 trans-signaling promotes KRAS-driven lung carcinogenesis","author":"Brooks","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0035","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2174\/1874467210902020190","article-title":"Malignant mesothelioma: biology, diagnosis and therapeutic approaches","volume":"2","author":"Tomasetti","year":"2009","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0040","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-09-1595","article-title":"Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma","volume":"69","author":"Goto","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0045","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.bbagrm.2010.05.005","article-title":"Interplay between microRNAs and the epigenetic machinery: an intricate network","volume":"1799","author":"Iorio","year":"2010","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fonc.2013.00261","article-title":"Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy","volume":"3","author":"Jakopovic","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/ijms17050627","article-title":"New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies","volume":"17","author":"Larrea","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-61779-612-8_1","article-title":"Epigenetic markers of early tumor development","volume":"863","author":"Dumitrescu","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0065","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1634\/theoncologist.7-5-451","article-title":"Aberrant DNA methylation in lung cancer: biological and clinical implications","volume":"7","author":"Z\u00f6chbauer-M\u00fcller","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nature10275","article-title":"A continuum model for tumour suppression","volume":"476","author":"Berger","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0075","article-title":"Is lung cancer incidence increasing in never-smokers?","volume":"108","author":"Su","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0080","article-title":"Small cell lung cancer in never-smokers","author":"Torres-Dur\u00e1n","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0085","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/bjc.2015.324","article-title":"Lung cancer risk at low radon exposure rates in German uranium miners","volume":"113","author":"Kreuzer","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1476-069X-11-89","article-title":"Arsenic, asbestos and radon: emerging players in lung tumorigenesis","volume":"11","author":"Hubaux","year":"2012","journal-title":"Environ. Health"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0095","doi-asserted-by":"crossref","first-page":"e0135798","DOI":"10.1371\/journal.pone.0135798","article-title":"Additive synergism between asbestos and smoking in lung cancer risk: a systematic review and meta-Analysis","volume":"10","author":"Ngamwong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1539\/joh.48.261","article-title":"Aberrant promoter methylation of p16(INK4a) and O(6)-methylguanine-DNA methyltransferase genes in workers at a Chinese uranium mine","volume":"48","author":"Su","year":"2006","journal-title":"J. Occup. Health"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0105","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ejca.2005.02.020","article-title":"CpG island methylation and expression of tumour-associated genes in lung carcinoma","volume":"41","author":"Dammann","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0110","doi-asserted-by":"crossref","first-page":"e60107","DOI":"10.1371\/journal.pone.0060107","article-title":"Association between P(16INK4a) promoter methylation and non-small cell lung cancer: a meta-analysis","volume":"8","author":"Gu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0115","doi-asserted-by":"crossref","first-page":"8897","DOI":"10.1038\/srep08897","article-title":"Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients","volume":"5","author":"Huang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0120","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMoa0706550","article-title":"DNA methylation markers and early recurrence in stage I lung cancer","volume":"358","author":"Brock","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0125","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00432-009-0614-4","article-title":"RASSF1A, APC ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China","volume":"135","author":"Lin","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0130","first-page":"1675","article-title":"Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers","volume":"135","author":"Yano","year":"2009","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0135","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/cncr.23113","article-title":"Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features","volume":"110","author":"Kim","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2016.05.023_bib0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lungcan.2005.04.013","article-title":"Aberrant methylation of FBN2 in human non-small cell lung cancer","volume":"50","author":"Chen","year":"2005","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0145","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ijheh.2014.01.001","article-title":"The effects of environmental chemical carcinogens on the microRNA machinery","volume":"217","author":"Izzotti","year":"2014","journal-title":"Int. J. Hyg. Environ. Health"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0150","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/gcc.20880","article-title":"Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos- and histology-related changes in lung cancer","volume":"50","author":"Nymark","year":"2011","journal-title":"Genes. Chromosomes Cancer"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0155","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0160","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1073\/pnas.0712399105","article-title":"Transcriptome sequencing of malignant pleural mesothelioma tumors","volume":"105","author":"Sugarbaker","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0165","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-1-4939-1804-1_12","article-title":"Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options","volume":"1238","author":"Zhang","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0170","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.lungcan.2013.05.014","article-title":"The role of epigenetics in malignant pleural mesothelioma","volume":"81","author":"Vandermeers","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0175","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/carcin\/bgn059","article-title":"Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma","volume":"29","author":"Christensen","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0180","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/0008-5472.CAN-15-0295","article-title":"Germline BAP1 mutational landscape of asbestos-Exposed malignant mesothelioma patients with family history of cancer","volume":"76","author":"Ohar","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0185","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2006.06.017","article-title":"Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma","volume":"54","author":"Fischer","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0190","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/gcc.20669","article-title":"CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma \u2212A miRNA microarray analysis","volume":"48","author":"Guled","year":"2009","journal-title":"Genes. Chromosomes Cancer"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0195","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0b013e31820db125","article-title":"MicroRNAs dysregulation in human malignant pleural mesothelioma","volume":"6","author":"Balatti","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0200","doi-asserted-by":"crossref","first-page":"e18232","DOI":"10.1371\/journal.pone.0018232","article-title":"Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma","volume":"6","author":"Santarelli","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0205","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/cncy.21646","article-title":"Young investigator challenge: microRNA-21\/MicroRNA-126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology","volume":"124","author":"Cappellesso","year":"2016","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0210","doi-asserted-by":"crossref","first-page":"590148","DOI":"10.1155\/2015\/590148","article-title":"Malignant pleural mesothelioma outcomes in the era of combined platinum and folate antimetabolite chemotherapy","volume":"2015","author":"Saint-Pierre","year":"2015","journal-title":"Lung Cancer Int."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0215","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.lungcan.2015.09.013","article-title":"Role of circulating-tumor DNA analysis in non-small cell lung cancer","volume":"90","author":"Jiang","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0220","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40291-015-0167-y","article-title":"Role of circulating cell-Free DNA in cancers","volume":"19","author":"Aarthy","year":"2015","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0225","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci, Transl. Med."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0230","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0235","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/fon.12.192","article-title":"Circulating miRNAs as new blood-based biomarkers for solid cancers","volume":"9","author":"Redova","year":"2013","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0240","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/med.20215","article-title":"Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers","volume":"32","author":"Zen","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0245","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1073\/pnas.1019055108","article-title":"Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma","volume":"108","author":"Arroyo","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0250","first-page":"21","article-title":"Extracellular vesicle transfer of cancer pathogenic component","author":"Fujita","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0255","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1158\/0008-5472.CAN-12-2309","article-title":"DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer","volume":"72","author":"Nikolaidis","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0260","doi-asserted-by":"crossref","first-page":"6842","DOI":"10.1158\/1078-0432.CCR-13-0736","article-title":"Epigenetic inactivation of microRNA-34b\/c predicts poor disease-free survival in early-stage lung adenocarcinoma","volume":"19","author":"Nadal","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0265","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1200\/JCO.2012.48.5516","article-title":"A prognostic DNA methylation signature for stage I non-small-cell lung cancer","volume":"31","author":"Sandoval","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0270","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0275","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1373\/clinchem.2008.121962","article-title":"PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics prognostics, and response to treatment","volume":"55","author":"Kristensen","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0280","first-page":"3782","article-title":"p16INK4A Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer","volume":"8","author":"Bearzatto","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0285","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.lungcan.2013.05.016","article-title":"Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients","volume":"81","author":"Ponomaryova","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0290","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2015-0776","article-title":"SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer","author":"Balgkouranidou","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0295","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/ijc.27981","article-title":"Meta-analysis of microRNA expression in lung cancer","volume":"132","author":"V\u00f5sa","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0300","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biopha.2011.09.004","article-title":"A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer","volume":"66","author":"Gao","year":"2012","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0305","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00432-010-0918-4","article-title":"MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis","volume":"137","author":"Gao","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0310","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/1471-2407-11-393","article-title":"Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study","volume":"11","author":"Zhu","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0315","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1200\/JCO.2008.19.4134","article-title":"Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma","volume":"27","author":"Lebanony","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0320","doi-asserted-by":"crossref","first-page":"e29671","DOI":"10.1371\/journal.pone.0029671","article-title":"MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer","volume":"7","author":"Donnem","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0325","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1073\/pnas.1100048108","article-title":"MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer","volume":"108","author":"Boeri","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0330","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/ijc.26177","article-title":"Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for non-small cell lung cancer diagnosis","volume":"130","author":"Chen","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0335","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1073\/pnas.0510565103","article-title":"A microRNA expression signature of human solid tumors defines cancer gene targets","volume":"103","author":"Volinia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0340","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5662\/wjm.v4.i2.59","article-title":"MicroRNAs in lung cancer","volume":"4","author":"Joshi","year":"2014","journal-title":"World J. Methodol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0345","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.2013.50.4357","article-title":"Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study","volume":"32","author":"Sozzi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0350","doi-asserted-by":"crossref","first-page":"19478","DOI":"10.1074\/jbc.M110.217331","article-title":"Thrombomodulin is silenced in malignant mesothelioma by a poly(ADP-ribose) polymerase-1-mediated epigenetic mechanism","volume":"286","author":"Nocchi","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0355","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1046\/j.1538-7836.2003.00306.x","article-title":"Thrombomodulin","volume":"1","author":"Weiler","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0360","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/mc.20663","article-title":"Decreased expression of thrombomodulin is correlated with tumor cell invasiveness and poor prognosis in nonsmall cell lung cancer","volume":"49","author":"Liu","year":"2010","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0365","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.lungcan.2015.09.021","article-title":"Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma","volume":"90","author":"Santarelli","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0370","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jmoldx.2014.03.002","article-title":"Diagnostic potential of miR-126 miR-143, miR-145, and miR-652 in malignant pleural mesothelioma","volume":"16","author":"Andersen","year":"2014","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0375","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/onc.2013.476","article-title":"Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma","volume":"33","author":"Cioce","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0380","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.molonc.2014.11.007","article-title":"MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma","volume":"9","author":"Kirschner","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0385","doi-asserted-by":"crossref","first-page":"e0135331","DOI":"10.1371\/journal.pone.0135331","article-title":"Two different serum MiRNA signatures correlate with the clinical outcome and histological subtype in pleural malignant mesothelioma patients","volume":"10","author":"Lamberti","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0390","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0395","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clinbiochem.2012.02.009","article-title":"Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients","volume":"45","author":"Tomasetti","year":"2012","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0400","doi-asserted-by":"crossref","first-page":"e30221","DOI":"10.1371\/journal.pone.0030221","article-title":"Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma-a pilot study","volume":"7","author":"Weber","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0405","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0410","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4161\/epi.6.8.16074","article-title":"The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma","volume":"6","author":"Nelson","year":"2011","journal-title":"Epigenetics"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0415","doi-asserted-by":"crossref","first-page":"e114483","DOI":"10.1371\/journal.pone.0114483","article-title":"Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis","volume":"9","author":"Weber","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0420","first-page":"1","article-title":"Using epigenetic therapy to overcome chemotherapy resistance","volume":"36","author":"Strauss","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0425","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0430","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1158\/1078-0432.CCR-10-2986","article-title":"Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts","volume":"17","author":"Takenouchi","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0435","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1016\/j.vaccine.2011.05.029","article-title":"Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth","volume":"29","author":"Guillot","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0440","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/cbic.201402449","article-title":"miRNA and methylation: a multifaceted liaison","volume":"16","author":"Chhabra","year":"2015","journal-title":"Chembiochem"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0445","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbrc.2008.12.098","article-title":"Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells","volume":"379","author":"Saito","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0450","article-title":"MicroRNA-187-3p mitigates non-small cell lung cancer (NSCLC) development through down-regulation of BCL6","author":"Sun","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0455","article-title":"Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0460","article-title":"MicroRNA-26b suppresses the metastasis of non-small cell lung cancer by targeting MIEN1 via NF-\u03baB\/MMP-9\/VEGF pathways","author":"Li","year":"2016","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0465","first-page":"14235","article-title":"MiR-152 regulates metastases of non-small cell lung cancer cells by targeting neuropilin-1","volume":"8","author":"Zhang","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0470","doi-asserted-by":"crossref","first-page":"E3553","DOI":"10.1073\/pnas.1412686111","article-title":"Small RNA combination therapy for lung cancer","volume":"111","author":"Xue","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0475","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/mt.2011.48","article-title":"Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice","volume":"19","author":"Trang","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0480","first-page":"2014","article-title":"A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer","author":"Kasinski","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2016.05.023_bib0485","doi-asserted-by":"crossref","first-page":"e1413","DOI":"10.1038\/cddis.2014.380","article-title":"Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation","volume":"5","author":"Yan","year":"2014","journal-title":"Cell. Death. Dis."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0490","first-page":"6223","article-title":"Methylation-associated silencing of microRNA-126 and its host gene EGFL7 in malignant pleural mesothelioma","volume":"35","author":"Andersen","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0495","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1089\/ars.2013.5215","article-title":"MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function","volume":"21","author":"Tomasetti","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0500","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2016.05.023_bib0505","first-page":"23","article-title":"Preclinical evaluation of microRNA-34b\/c delivery for malignant pleural mesothelioma","volume":"68","author":"Ueno","year":"2014","journal-title":"Acta Med. Okayama"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216303506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216303506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T12:55:11Z","timestamp":1536670511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216303506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":101,"alternative-id":["S0169500216303506"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.05.023","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}